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Cardiovascular diseases (CVDs), including thrombosis, which is induced by platelet
aggregation, are the leading cause of mortality worldwide. The P2Y1 receptor (P2Y1R)
facilitates platelet aggregation and is thus an important potential anti-thrombotic drug
target. The P2Y1R protein structure contains a binding site for receptor antagonist
MRS2500 within its seven-transmembrane bundle, which also provides suitable pockets
for numerous other ligands to act as nucleotide antagonists of P2Y1R. The Traditional
Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP)
comprises 499 Chinese Pharmacopoeia-registered herbs and the structure information
for 29,384 ingredients. In silico docking of these compounds into the P2Y1R protein
structure within the MRS2500 pocket can identify potential antithrombotic drugs from
natural medicinal plants. Docking studies were performed and scored to evaluate
ligand-binding affinities. In this study, a total of 8987 compounds from Traditional Chinese
Medicine (TCM) were filtered by Lipinski’s rule of five, and their ideal oral-intake properties
were evaluated. Of these, 1656 compounds distributed in 443 herbs docked into the
P2Y1R-MRS2500 structure in 16,317 poses. A total of 38 compounds were ranked with
a DockScore above 70, and these may have significant potential for development into
anti-thrombosis drugs. These computational results suggested that licorice (Glycyrrhiza
uralensis Fisch), cimicifugae (Cimicifuga foetida L.), and ganoderma (Ganoderma lucidum
Karst) and their chemical constituents, which have not previously been widely used for
anti-thrombosis, may have unexpected effects on platelet aggregation. Moreover, two
types of triterpene scaffolds summarized from 10 compounds were distributed in these
three herbs and also docked into P2Y1R. These scaffold structures may be utilized for
the development of drugs to inhibit platelet aggregation.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of mortality worldwide. CVD is multifactorial,
and its risk factors include stroke, hypertension, arrhythmias, and thrombosis (Mozaffarian et al.,
2016). Platelet aggregation-induced thrombosis obstructs blood circulation, playing a central role
in acute, and chronic arterial vascular diseases (Radomski et al., 2005). Antiplatelet drugs decrease
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thrombus formation, and their estimated market is worth 24
billion United States dollars (USD).
G protein-coupled P2Y receptors belong to the nucleotide
receptor G protein-coupled receptor (GPCR) family and
have eight mammalian subtypes (P2Y1,2,4,6,11-14) (Kim et al.,
2003). P2Y1 and P2Y12 belong to the human purinergic
GPCRs and can be activated by adenosine 5′-diphosphate
(ADP) to induce platelet activation (Gurbel et al., 2015).
ADP is the first small-molecular weight platelet agonist,
and its receptors, such as P2Y1 receptors, can couple to
activated phospholipase C. The activation of serotonin receptor
supplements signaling through the P2Y1 receptor, demonstrating
that it is a specific antagonist able to block ADP-induced platelet
aggregation (Jin and Kunapuli, 1998). The human P2Y1
receptor protein structure and its two ligand-binding sites
for the nucleotide-like antagonist MRS2500 and allosteric
antagonist 1-(2-(2-tert-butylphenoxy)pyridin-3-yl)-3-(4-
(trifluoromethoxy)phenyl)urea (BPTU) were reported in 2015
(Protein Database [PDB] ID: 4XNW, 4XNV) (Zhang et al.,
2015). (1′R,2′S,4′S,5′S)-4-(2-Iodo-6-methylaminopurin-9-yl)-
1-[(phosphato) methyl]-2(phosphato)bicycle[3.1.0]-hexane
(MRS2500) is a reported antagonist candidate that exerts its
effect via its unique chemical structure. This compound binds
the recombinant human P2Y1 receptor and inhibits the platelet
aggregation caused byADPwith an 50% inhibitory concentration
(IC50) value in the nanomolar range. It also effectively reduces
arterial thrombosis and prolongs bleeding time and has been
evaluated as a prototypical antithrombotic agent both ex vivo
and in vivo (Hechler et al., 2006). Unlike P2Y12R, P2Y1R has a
highly conserved in class A GPCR residue P229. The pocket for
MRS2500 binding to P2Y1R mainly defined by residues from
the N terminus, ECL2, and its helices structures. In P2Y1R, the
antagonist MRS2500 potentially prevents the movements of
these helices and stabilized the receptor in an inactive state by
interacting with helices In the P2Y1R–MRS2500 structure, each
terminal oxygen of the two phosphates forms at least one contact
with the receptor. The hydrogen bonds from 3′-phosphate with
Arg195 and Thr201, meanwhile, it is engaged in two salt-bridge
interactions with Lys46 at the N terminus. The 5′-phosphate
forms a salt-bridge with Thr205 and makes hydrogen bonds
with Asp204 and Arg310. P2Y1R and P2Y12R structures reveal
very different features in binding their nucleotide-like ligands
even though recognized by the same endogenous ligand ADP.
Most significantly, the binding site of MRS2500 in P2Y1R locates
much closer to the extracellular surface than the other known
GPCR structures affiliated small-molecule ligand-binding sites.
Due to its more safety advantage over the P2Y1R inhibitors of
reducing bleeding liabilities than P2Y12R, it has been suggested to
discovery as a whole new drug targets (Gachet, 2008). Moreover,
the P2Y1R is also enrolled in other procedure in human body,
such as activation of extracellular signal-regulated kinase in
astrocytes and vascular inflammation (Zerr et al., 2011). In
recent years, many study were performed on P2Y12R, however,
the P2Y1R protein and its ligand pocket crystal structure was
firstly reported in 2015. And P2Y1R has the specificity bind-
model and its diversity of regulation mechanisms compared with
P2Y12R. This give us a hit that it is easier for other unknown
small-molecule can binding to the pocket and thus be a potential
antagonist of P2Y1R.
Traditional Chinese Medicines (TCMs) is a relevant source
of biological compounds with innovative mechanisms of action.
Although TCMs concepts diverge from Western medicine,
concepts, some correlations exist between the two systems.
For example, Huoxuehuayu promotes blood circulation and
alleviates blood stasis. Several compounds, including ligustrazine,
saffionin A, resveratrol, propylgallate, notoginseng triterpenes,
crudione, lerulic acid, salvianolic acid A and B, tanshinone IIA,
and saﬄower flavin, which are extracted from the TCM herbs:
Salvia miltiorrhiza Bge., Rheum palmatum L., and Ligusticum
chuanxiong hort., can inhibit platelet aggregation induced by
arachidonic acid (AA), ADP, platelet-activating factor (PAF)
and collagen or thrombin both in vivo and in vitro (Chen,
1981). Moreover, because the mechanism of thrombosis involves
multiple pathways and requires a multi-target approach for
treatment, various small molecule compounds that are not
limited to the TCMs activity for the treatment of platelet
aggregation can be used to target different proteins, tissues
and organs. Therefore, other TCM plants and their active
ingredients may act on the P2Y1 receptor protein to inhibit
platelet aggregation via an innovative approach.
Computational approaches have been widely applied to
molecular biology and medicinal research. Structure-based
methods, such as ligand-protein docking, are efficient and
reliable tools for novel drug discovery and design. In silico
docking can elucidate the interactions and binding mechanisms
between the protein target and its suitable ligands. The
Traditional Chinese Medicine Systems Pharmacology Database
and Analysis Platform (TCMSP) comprises all 499 Chinese herbs
registered in the Chinese Pharmacopoeia and 29,384 ingredients
(Ru et al., 2014). The TCMSP provides a total of twelve
absorption, distribution, metabolism, and excretion (ADME)-
related properties, including oral bioavailability and half-life.
The objective of this study was to use an in silico docking
approach to investigate the potential of compounds in the
TCMSP and their distributed herbs as P2Y1R antagonists and
potential new antiplatelet drugs. In this study, we collected all the
information of herbs and their contained ingredients from the
TCMSP. Then performing the docking procedure of these total
29,384 compounds into the pocket structure of receptor P2Y1R.
Analyzed results of these high efficient docked compounds,
summarized there general characters such as scaffold and there
distributed herbs will provide a new direction in antiplatelet
drugs innovation.
MATERIALS AND METHODS
Software
The 2-dimensional (2D) and 3D structures of TCM compounds
were drawn using ChemBioOffice 2010 (PerkinElmer Inc.,
Cambridge, MA, USA) and MarvinSketch V15.8 (ChemAxon
Ltd., Budapest, Hungary). The P2Y1 protein and MRS2500
structure (PDB ID: 4XNW) were downloaded from the
PDB database (http://www.rcsb.org/pdb) and optimized with
Molecular Operating Environment (MOE) 2014.09 (Chemical
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Computing Group Inc., Montreal, QC, Canada). Candidate
compounds were downloaded from the TCMSP database (http://
lsp.nwsuaf.edu.cn/tcmsp.php). The chemical structure format
was transformed by OpenBabelGUI (O’Boyle et al., 2011) version
2.3.2 (OpenBableGUI 2006 by Chris Morley). Virtual screening
was performed using Discovery Studio Client V4.5 (DS 4.5;
Accelrys Inc., San Diego, CA, USA). The network and functional
analyses were generated using QIAGEN’s Ingenuity Pathway
Analysis (IPA R©, QIAGEN Redwood City, CA, USA; http://www.
qiagen.com/ingenuity).
Lipinski’s Rule of Five and ADME/Toxicity
(T) Predictions
Those compounds collected in the TCMSP database were
evaluated for Lipinski’s rule of five (RO5; Lipinski et al.,
2012) before screening. Poor pharmacokinetics and toxicity
are important causes of costly failures during the downstream
process of drug development. This evaluation procedure was
performed in DS 4.5, the “filter by Lipinski and Veber Rules”
which located in “Small Molecules” module. All setting as
default values which individual property thresholds according
to the original publications. Their ADME/T properties (van
de Waterbeemd and Gifford, 2003) must be predicted and
are now computable with in silico approaches, accelerating
the drug discovery process. Therefore, we can also filter and
design drug-like molecules. The DS 4.5 ADME/T Description
module was used to predict the pharmacokinetic properties of all
candidate compounds. This program offers reliable predictions
for pharmaceutically relevant properties, including aqueous
solubility, blood-brain barrier penetration (BBP), cytochrome
P450 2D6 inhibition, hepatotoxicity, human intestinal absorption
(HIA), and plasma protein binding. The ADME/T Description
predicts the physically significant descriptors of pharmaceutically
relevant properties of organic molecules. The BBP-95&99 and
Absorption-95&99 confidence intervals are demonstrated as four
elliptical rings in the ADME/T_AlogP98 & ADME/T_PSA_2D
(Y–X axis) coordinate system.
Docking Analysis
The virtual screening docking process was performed with the
LigandFit module. LigandFit gives the best poses at the binding
site using a stochastic conformational search and the energy of
the ligand-protein complex (Sato et al., 2006). Compounds from
the TCMSP database were docked to the P2Y1 protein active
site fit for MRS2500 reported by Zhang (Zhang et al., 2015).
All procedures were completed using Chemistry at HARvard
Molecular Mechanics (CHARMm; Brooks et al., 2009). The
3D multi-conformational compound molecular structures were
generated using Monte Carlo algorithm-based conformational
analysis and rigid body minimization completed using the Smart
Minimizer module. The DockScore was adopted as the LigandFit
scoring to rank the TCMSP compounds that docked into
the P2Y1R ligand-binding pocket for MRS2500. The LigandFit
docking procedure consists of the following two steps: (1)
identify and select the region of the protein as the active site
for docking by cavity detection and (2) dock the candidate
ligands to the selected site. The docking cavity was defined
using the DS site search module. For all potential drugs, the
docking site was derived from the position of the MRS2500
and P2Y1 co-crystallized construction (PDB ID: 4XNW), and
the grid resolution was set to 0.5 Å (default). The ligand-
accessible grid was defined as the minimum distance between
a grid point and the protein and was 2.0 Å for hydrogen
and 2.5 Å for heavy atoms. This confirmed binding site was
used to calculate the non-bonded interactions between all
potential compounds and the P2Y1 receptor protein residues.
The docking procedure was initiated with the generation of
random ligand conformations. The following procedures were
performed after a new conformation was generated: The shapes
of the potential ligands were compared with the active site, and
if the result was acceptable, the dock energy (DockScore) was
computed between the protein and ligand trial conformation.
Variable numbers of Monte Carlo steps were used to generate
different ligand conformations. Scoring was performed with six
scoring functions: DockScore, LigScore 1 and 2, Piecewise Linear
Potential (PLP) 1 and 2, and Potential of Mean Force (PMF). We
assumed that the bioactive orientations ranked byDockScore and
other scoring functions were used to retain each molecule and
compute the enrichment factors.
RESULTS AND DISCUSSION
Screening and Structure Analysis
Figure 1 summarizes the technology roadmap and the screening
results after each step. In 1997, Lipinski led to the well-
known “Rule of Five” (RO5) for selecting drug-like molecules,
which demonstrated orally administered drugs should have
good oral bioavailability in order to be effective. According
to the “Rule of Five,” a drug-like molecule should have no
more than one of the following criterias: No more than five
hydrogen bond donors, no more than 10 hydrogen bond
acceptors, a molecular mass <500 daltons, and an octanol-
water partition coefficient log P not >5. To ensure this study
with a reliable and available results. All compounds need to
filtered by the RO5. From the 29,384 native TCM compounds
collected from the TCMSP database, 8987 compounds were
filtered by Lipinski’s rule of five and prepared for further study.
Successful docking to P2Y1R was observed for 1656 compounds
(16,317 poses), and their ADME/T descriptors were calculated
(Figure 2, Supplementary Datasheet 1). According to the DS 4.5
suggested theory, the Human Intestinal Absorption (HIA) model
can embodied in ADMET plot the validate the predictions. The
ADMET—Human Intestinal Absorption model predicts human
intestinal absorption (HIA) after oral administration. Intestinal
absorption is defined as a percentage absorbed rather than as a
ratio of concentrations. A well-absorbed compound is one that
is absorbed at least 90% into the bloodstream in humans. These
levels are defined by the 95% (red line) and 99% (green line)
confidence ellipsoids in Figure 2. For the ADME/T_PSA_2D,
ADME/T_AlogP98 plane, two confidence ellipsoids of 95 and
99% for oral absorption surrounded most of these natural
compounds. Two ellipsoids of 95 and 99% for BBP with high
penetrations further refined the range of compounds suitable for
clinical development as oral-intake drugs. Total view of these
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FIGURE 1 | Methodology roadmap and major results for P2Y1R-related
anti-thrombosis drug design from the TCMSP database.
1656 compounds, majority number within an acceptable range
which indicated that most candidates compounds have an ideal
human intestinal absorption which can further refined the range
of compounds suitable for clinical development as oral-intake
drugs. Candidate ligand poses can be evaluated and prioritized
according to the DockScore function. Each docked compound
has an optimal pose indicated by its highest DockScore. A total of
38 compounds had a DockScore above 70.0, and these presented
high potential for further studies (Table 1).
Traditional Chinese Herb Analysis
Although many TCMs are considered useful for treating CVDs,
each herb contains numerous compounds with different P2Y1R
DockScores. A total DockScore was obtained for each herb by
summing the DockScores of its compounds as recorded in the
TCMSP (Figure S1). Figure 3 shows the 10 herbs that possessed
the highest total DockScores. The IPA indicated that 1890
compounds present in these 10 herbs may be considered drug
candidates for hematological diseases and CVDs (Figure S2).
Additional GPCRs were mapped by the software.
Hydroxycarboxylic acid receptor 2 (HCAR2), a common
target for the widely prescribed dyslipidemia drug niacin, is
associated with platelet aggregation inhibition (Pike, 2005). In
addition, data indicate that the proto-oncogene tyrosine-protein
kinase (SRC), phosphoinositide 3-kinase (PI3K), mitogen-
activated protein kinase (MAPK), N-methyl-D-aspartate
receptor (NMDAR), receptor tyrosine-protein kinase erbB-2
(ERBB2), nuclear factor kappa-light-chain-enhancer of activated
B cells (NF-kB), and protein kinase a (Pka) pathways (Figure 4)
are activated by the top 10 herbs.
Candidate Compound Analysis
Sixteen compounds were associated with platelet aggregation,
and all of the relevant herbs were validated in the literature, as
shown in Table 2. Among them, ascorbic acid, also known as
vitamin C, is a well-known dietary antioxidant that inactivates
oxygen free radicals and exerts a variety of protective effects
on blood vessels and platelets (Yang et al., 2015). Vitexin and
caffeic acid showed significant antiplatelet aggregation activity
and were relatively selective inhibitors of platelet aggregation
induced by AA and collagen (Afifi and Abu-Dahab, 2012;
Lee and Bae, 2015). Rutin, naringin and quercetin, three
flavonoid glycosides, were metabolized to phenolic acids via
aglycones by human intestinal microflora and have been
considered natural prodrugs with anti-platelet activity since
the 1990s (Ndhlala et al., 2015). Esculetin is a derivative of
coumarin and exists as glycosides and caffeic acid conjugates
in Cimicifugae Rhizoma (Cimicifuga foetida L.) and many other
medicinal plants. The systemic usage of esculetin-containing
preparations has an anticoagulant effect and may interact with
anticoagulant drugs, such as warfarin (Karnewar et al., 2016).
Curcumin, a major component of turmeric, is also found in
Cimicifuga foetida L. and inhibits arachidonate-, adrenaline-,
and collagen-induced platelet aggregation. Curcumin inhibited
exogenous arachidonate-produced thromboxane B2 (TXB2)
in washed platelets and the incorporation of [14C]AA
into platelet phospholipids. Moreover, it also inhibited the
deacylation of AA-labeled phospholipids (Du et al., 2016).
Citric acid and L-malic acid, two main organic acids in Fructus
Choerospondiatis [Choerospondias axillaris (Roxb.) Burtt et Hill]
and Lycii Fructus (Lycium chinense Mill.), possess antioxidant,
anti-inflammatory, and antiplatelet aggregation activities
(Tang et al., 2013).
Cimicifugae, Ganoderma, and Licorice
Analysis
According to the dual analyses of results related to both
these compounds and plants, we focused on three particular
TCM herbs, cimicifugae (Cimicifuga foetida L.), ganoderma
(Ganoderma lucidum Karst), and licorice (Glycyrrhiza uralensis
Fisch).
Cimicifugae (Cimicifuga foetida L.) (also known as black
cohosh, black snakeroot, and rattlesnake root) has a long
tradition of use as a beneficial herbal remedy for joints, muscles,
nerve aches, and gynecological disorders in both China and
North America. Cimicifugae is used as an anti-inflammatory,
analgesic and antipyretic remedy in TCM.However, there are few
reports of its clinical use in anti-thrombosis. Sodium ferulate (SF)
is an active principle compound from cimicifugae and has been
used in TCM and approved by the State Drug Administration of
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FIGURE 2 | ADME/T prediction plots for compounds that successfully docked in P2Y1R (1656) from among the compounds in the TCMSP database.
China for the treatment of cardiovascular and cerebrovascular
diseases. SF has antithrombotic, platelet aggregation
inhibitory, and antioxidant activities in both animals and
humans.
Ganoderma (Ganoderma lucidum Karst) is a popular
medicinal mushroom and has been used in TCM in Asia
for the past two millennia to treat numerous diseases. Its
regular consumption is believed to preserve human vitality and
promote longevity. Ganoderma has been used worldwide, and
its constituents have been extensively identified; however,
the biological potency of this fungus has not yet been
sufficiently investigated. According to clinical observations
and pharmacologic experiments, ganoderma can improve
microcirculation in organs and increase the amount of blood.
Moreover, in recent years, a series studies focused on ganoderma
and anti-thrombosis (Kawagishi et al., 1993). The administration
of this herb in vitro and in vivo was found to significantly
inhibit ADP-induced platelet aggregation. These inhibitory
effects may involve the release of intrinsic ADP from platelets
or the metabolites of AA and PAF. Other research showed
that purified ganoderma fibrinolytic protease protected mice
against thrombotic death or paralysis induced by collagen and
epinephrine and also activated the partial thromboplastin time
(APTT) and thrombin time (TT) in rat platelets (Kumaran
et al., 2011). The polysaccharide of ganoderma was also found
to prolong the blood clotting and bleeding time in rats and
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TABLE 1 | Docking results of the top 38 (DockScore > 70) and their plant sources.
Molecule Name Pubchem_CID DockScore TCMs
Ganoderic acid J 20055991 78.772 Ganoderma lucidum Karst
Cimiside E 399180 78.104 Cimicifuga foetida L.
6′′-O-Acetylliquiritin 101051311 77.347 Glycyrrhiza uralensis Fisch
7,8-Didehydrocimigenol 101577840 76.088 Cimicifuga foetida L.
(2S,6R)-6-[(5R,7S,10S,13R,14R,17R)-7-Hydroxy-
4,4,10,13,14-pentamethyl-3,11,15-trioxo-
1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-
17-yl]-2-methyl-4-oxoheptanoic
acid
10481601 75.198 Ganoderma lucidum Karst
Cimicifoetiside A 16019999 74.951 Cimicifuga foetida L.
2′,7-Dihydroxy-4′-methoxyisoflavan-7-O-β-d-
glucopyranoside
/ 74.906 Glycyrrhiza uralensis Fisch
Lappaol C 323896 74.793 Arctium lappa L.
Diosgenin glucoside 65609 74.599 Asparagus cochinchinensis (Lour.) Merr.
2-(2-Phenylethyl)-6-[[(5S,6R,7R,8S)-5,6,7-trihydroxy-4-
keto-2-(2-phenylethyl)-5,6,7,8-tetrahydrochromen-8-
yl]oxy]chromone
14283395 74.349 Sinapis alba L.
Alisol C monoacetate 14036813 74.331 Alisma orientale (Samuels) Juzep.
Ganoderic acid E 23247894 74.216 Ganoderma lucidum Karst
Ononin 442813 74.078 Hedysarum multijugum Maxim.
STOCK1N-49993 16401117 73.833 Fritillaria cirrhosa D. Don
Cimigenol 16020000 73.833 Cimicifuga foetida L.
Lappadilactone 11081540 73.678 Rosa banksiae Ait.
Glyasperin E 392442 73.281 Glycyrrhiza uralensis Fisch
Ganodermic acid Q 10436380 73.28 Ganoderma lucidum Karst
Sophojaponicin 6326060 73.071 Euchresta japonica Hook. f. ex Regel Rheum officinale Baill.
Picroside III 24121289 72.681 Neopicrorhiza scrophulariiflora (Pennell) D.Y.Hong
Hirsutaside C / 72.612 Uncaria sinensis (Oliv.) Havil.
Avenacoside A 71581001 72.551 Lilium brownii var. viridulum Baker
Fichotomide I 11244683 72.09 Gypsophila licentiana Hand.-Mazz.
Dioscoreside C_qt 52931427 71.807 Dioscorea opposite L.
Sanggenol A 15233693 71.63 Morus alba L.
Bisdehydroprotostemonine 101675309 71.562 Stemona japonica (Blume) Miq.
Cubebinone 91724200 71.561 Litsea cubeba (Lour.) Pers.
9,10-Dihydrophenanthrene-9,10-diol 99889 71.502 Bletilla striata (Thunb.) Rchb.f.
Convallasaponin A 441883 71.339 Polygonatum odoratum (Mill.) Druce
Yuccagenin 3083608 71.245 Trigonella foenum-graecum L.
Methyl (4R)-4-[(5R,10S,13R,14R,17R)-4,4,10,13,14-
Pentamethyl-3,7,11,15-tetraoxo-2,5,6,12,16,17-
hexahydro-1H-cyclopenta[a]phenanthren-17-
yl]pentanoate
21633085 70.88 Ganoderma lucidum Karst
Hydnocarpin 5489114 70.561 Lonicera japonica Thunb.
Ganoderic acid C2 57396771 70.305 Ganoderma lucidum Karst
Kaikasaponin III_qt 188384 70.207 Abrus precatorius L.
Trifolirhizin 442827 70.192 Panax notoginseng (Burkill) F.H.Chen
Pyrrosia lingua (Thunb.) Farw.
Sophora flavescens Aiton
Cimicifugoside H1 15241163 70.1 Cimicifuga foetida L.
27-Hydroxywithanolide B 44576309 70.041 Datura metel L.
Kuwanon F 156149 70.023 Morus alba L.
MRS2500 44448831 Control Synthetic Compounds
Bold font indicates the three ideal plants found in this article: licorice, cimicifugae, and ganoderma.
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decrease the thrombosis and fibrinogen level in blood plasma
(Klupp et al., 2016). Evidence indicates that ganoderma has
potential as an antithrombotic herb because of its antiplatelet
activity.
FIGURE 3 | Top 10 herbs selected by estimating the number of hit
compounds (orange area between bars), max DockScore (pink line)
and total DockScore (blue bars).
Licorice (Glycyrrhiza uralensis Fisch; Chinese name Gan-cao)
is one of the most indispensable crude drugs in TCM
preparations (constituting ∼60%), and its wide clinical use
widely began in ancient Egyptian, Greek and China in the
Second century B.C. Licorice comprises the roots of three
Glycyrrhiza species (Glycyrrhiza uralensis Fisch, Glycyrrhiza
glabra L., and Glycyrrhiza inflata Batalin). In traditional
clinical treatment, this botanical drug is typically used for
allergic-inflammatory disease, gastrointestinal problems, cancer,
CVD, and bladder and kidney ailments. Approximately 300
diverse compounds have been isolated from licorice, including
triterpene saponins and flavonoids, which are responsible for the
antiviral, anti-inflammatory, antitumor, antitussive, anti-oxidant,
antispasmodic, and metabolic syndrome preventive activities.
However, evidence suggests that licorice has anti-thrombosis
activity and can be used to treat CVDs.
These three herbs contained 14 compounds with a DockScore
above 70 (Table 3). By calculating the binding energies between
P2Y1R and these 14 compounds, the binding efficiency and loss
of conformational entropy and energy of a bound ligand can
be obtained. These compounds have different ranges of ligand
energies, Van der Waals energies and bond energies compared
with the ligand MRS2500. However, according to CHARMm
command-based calculations, all 14 have similar rotational and
FIGURE 4 | IPA-mapped CVD pathway for the 1890 compounds distributed in the top 10 herbs.
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TABLE 2 | Compounds related to platelet aggregation extracted from the
top 10 herbs.
Compounds* CAS ID Herbs
1 3,4-Dihydroxyphenylethanol 10597-60-1 Cimicifuga foetida L.
2 Caffeic acid 331-39-5 Cimicifuga foetida L.
3 Capsaicin 404-86-4 Panax quinquefolius L.
4 Cetulinic acid 472-15-1 Glycyrrhiza uralensis Fisch
5 Cholesterol 57-88-5 Commiphora myrrha (T.Nees)
Engl.
6 Chlorogenic acid 327-97-9 Panax notoginseng (Burkill)
F.H.Chen
7 Citric acid 43136-35-2 Lycium chinense Mill.
8 Cscorbic acid 50-81-7 Lycium chinense Mill.
9 Curcumin 458-37-7 Cimicifuga foetida L.
10 Esculetin 305-01-1 Cimicifuga foetida L.
11 Gallic acid 149-91-7 Gynostemma pentaphyllum
(Thunb.) Makino
Glycyrrhiza uralensis Fisch
Panax notoginseng (Burkill)
F.H.Chen
Cimicifuga foetida L.
Curcuma zedoaria (Christm.)
Roscoe
12 L-Malic acid 97-67-6 Lycium chinense Mill.
13 Naringin 10236-47-2 Glycyrrhiza uralensis Fisch
14 Quercetin 117-39-5 Gynostemma pentaphyllum
(Thunb.) Makino
Commiphora myrrha (T.Nees)
Engl.
Lycium chinense Mill.
Glycyrrhiza uralensis Fisch
15 Vitexin 3681-93-4 Glycyrrhiza uralensis Fisch
16 Rutin 153-18-4 Gynostemma pentaphyllum
(Thunb.) Makino
Lycium chinense Mill.
Glycyrrhiza uralensis Fisch
*Compound information provided by IPA. All compounds had clinical and/or experimental
validation determined by IPA chemical database screening. Bold font indicates the three
ideal plants found in this article: licorice, cimicifugae, and ganoderma.
translational entropy values, indicating that these compounds all
have the same effective binding efficiency as the original ligand
MRS2500 (Figure 5).
A drug-likeness (DL) analysis was performed to determine
whether these compounds have potential uses as drugs. The
DL index values of these compounds were calculated using
the Tanimoto coefficient and are presented in the TCMSP
database. A molecule with DL > 0.18 was considered a drug-
like compound and was selected for the following processes.
Cytochrome P450 2D6 (CYP2D6) is involved in the metabolism
of a wide range of substrates in the liver, and its inhibition is
related to most drug-drug interactions. The CYP2D6 model can
predict candidate compounds for CYP2D6 enzyme inhibition;
therefore, investigating CYP2D6 inhibition is a required part of
the regulatory procedures involved in the drug discovery and
development process. Discovery Studio ADME/T Descriptors
contain a computational model for compounds inhibiting the
CYP2D6 enzyme, which was developed from a training set
of 151 structurally diverse compounds with known CYP2D6
inhibition constants. This experiment was performed with
modified Bayesian learning, and all 14 compounds scored below
the cutoff Bayesian score of 0.161 and were not classified as
CYP2D6 inhibitors. Therefore, these compounds are unlikely
to have drug-drug interactions and can improve the efficiency
and safety of drugs, which has significant clinical importance.
The hepatotoxicity model can predict potential organ toxicity
and was developed from the available literature data for 436
compounds known to exhibit liver toxicity or trigger dose-related
elevated aminotransferase levels in more than 10% of the human
population. For these 14 compounds, eight had no hepatotoxic
activity, including four compounds from licorice (Table 4).
The scaffold and pharmacophore are two basic elements
of drug molecules. The pharmacophore consists of discrete
atoms, groups, and fragments responsible for the physic-
chemical features, and their arrangement controls the specific
activities. However, the pharmacophore must incorporate an
integrated scaffold to form an actual molecule, and thus,
implanting the same pharmacophore on various scaffolds results
in structurally diverse compounds that act on the same biological
target. The promiscuity of receptors indicates that scaffolds
can be rationally transformed based on the flexibility and
plasticity of the receptors, thereby imbuing receptor binding
sites with diversity and variability. Compared to traditional high-
throughput screening methods, the scaffold-based approach can
facilitate higher initial synthetic efforts guided by the co-crystal
structure.
Among these 14 compounds, two triterpene scaffolds are
found in 10 compounds. Scaffold 1 was found in compounds PD-
4, 5, 6, 7, 8, and 9, whereas scaffold 2 was found in compounds
PD-11, 12, 13, and 14 (Figure 6). These two scaffolds could
be further developed into more potent and selective drug-like
ligands by an iterative process including co-crystallography of
the complex constructed by candidate compounds with the
P2Y1R protein. These candidate compounds could subsequently
be used for chemical syntheses followed by structure-guided
computational design. An ideal DL scaffold should not
only form key interactions with the protein target but also
possess a conserved binding mode that can tolerate small
substitutions.
CONCLUSION
Platelet aggregation occurs when platelets adhere to each other
at sites of vascular injury. This process has long been recognized
as critical for hemostatic plug formation and thrombosis, which
is the final product of the aggregated platelets that formed a
platelet plug. Vitamin K antagonists and warfarin are often taken
orally to reduce thromboembolic occurrence; however, both of
these drugs have an unwanted side effect of an increased risk of
bleeding.
Uncontrolled platelet aggregation is critical in thrombosis,
which may cause heart attacks, unstable angina and other
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FIGURE 5 | Comparison of 14 compounds in the binding model structure with MRS2500.
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TABLE 4 | P2Y1R binding energies for compounds PD-1∼PD-14.
Compound Ligand
energy
Improper
energy
Angle
energy
Dihedral
energy
Electrostatic
energy
Van der
Waals
energy
RMS
gradient
Bond
energy
Rotational
entropy
Translational
entropy
Ligand
entropic
energy*
MRS2500 112.642 0.01780 37.4877 18.4862 31.3132 4.02 27.0966 21.3167 38.0197 32.3073 −20.968
PD-1 132.048 0.08685 53.3583 115.673 −34.8348 −21.7701 14.3482 19.5344 38.0119 32.3052 −20.965
PD-2 158.233 0.00162 40.7545 118.223 −0.04683 −23.6102 8.53944 22.9105 38.5017 32.5422 −21.1817
PD-3 173.499 0.00000 95.1922 83.3181 −11.2569 −14.6189 8.2638 20.864 37.2045 31.9167 −20.6085
PD-4 137.537 0.00781 35.496 85.7151 −38.3119 35.2412 25.7248 19.3887 37.7349 32.1738 −20.8433
PD-5 326.639 0.60045 50.483 136.935 27.8459 90.152 67.7923 20.6223 38.8614 32.6203 −21.3123
PD-6 80.7362 0.13864 26.5836 75.593 −35.1109 0.98494 17.0155 12.547 37.7973 32.1509 −20.8551
PD-7 85.0095 0.13282 30.6886 85.335 −32.4446 −10.3341 15.0403 11.6317 37.2454 31.8042 −20.5871
PD-8 104.733 0.06613 31.4111 89.5891 −38.5655 9.27464 20.1861 12.9572 37.6091 32.071 −20.7751
PD-9 72.005 0.10815 26.9039 75.2766 −34.1692 −8.48898 16.572 12.3746 37.9219 32.0593 −20.8649
PD-10 123.831 0.11197 31.7549 102.652 −40.3419 15.6907 18.6129 13.9629 38.125 32.0942 −20.9359
PD-11 77.6839 0.07226 27.2305 82.7531 −33.2483 −11.1572 14.5606 12.0335 37.7967 32.071 −20.8311
PD-12 51.0403 0.02020 13.3322 38.6903 −31.9949 −5.449 27.1373 36.4415 37.2514 31.6337 −20.5381
PD-13 113.581 0.00089 13.4249 43.8391 16.1906 4.25157 21.2566 35.8735 37.303 31.5659 −20.5333
PD-14 100.668 0.03287 8.12721 44.1692 8.49017 −6.09511 25.1593 45.9435 37.5527 31.634 −20.628
*Ligand entropic energy, rotational and translational entropy of the ligand (kcal/mol); rotational entropy, rotational entropy calculated from the principal moments of inertia for the ligand
(kcal/mol); translational entropy, corrected translational entropy for the ligand (kcal/mol).
FIGURE 6 | Two types of scaffolds in Cimicifuga foetida L., Ganoderma lucidum Karst, and Glycyrrhiza uralensis Fisch.
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systematic disorders. The inhibition of platelet aggregation
is fundamentally important in the treatment and prevention
of CVDs. Platelet aggregation can regulated by G protein-
coupled P2Y receptor families, particularly P2Y12 and P2Y1
(Aslam et al., 2013). P2Y1 is required for platelet shape
change in response to ADP and is also a principal receptor
in mediating both physiological and pathological ADP-
induced platelet aggregation. At higher ADP concentrations,
P2Y1-deficient platelets become partially aggregated. In
vivo, the bleeding time was increased by the lack of P2Y1
expression, which could protect against collagen- and ADP-
induced thrombosis. It is sufficient to block ADP-induced
platelet aggregation by utilize specific antagonists inhibit
the signaling through P2Y1 receptor (Jin and Kunapuli,
1998).
MRS2500 is a new antiplatelet drug that has strong
antithrombotic activity in systemic thromboembolism induced
by adrenaline infusion. In P2Y1R, the antagonist MRS2500
may prevent the movement of P2Y1R helix structures and
stabilize the receptor in an inactive state. The nucleotide-
like antagonist MRS2500 of P2Y1R has numerous anchor
points on different receptor domains in hydrophilic and
charged sites. The interactions of both P2Y1 and P2Y12R
with their nucleotide ligands reveal disparate binding
modes between these two P2YR subfamilies, broadening
our understanding of the diversity of signal-recognition
mechanisms in GPCRs and providing additional potential
ligands and diversity binding models to regulate the proteins
of these subfamilies. MRS2500 has is an ideal antagonist
of P2Y1R that can prevent platelet aggregation caused by
thrombosis.
The pharmacological actions of TCMs activate blood and
resolve stasis to treat thrombosis. Many Traditional Chinese
herbs and Chinese patent medicines are widely applied in
clinical use to treat thrombosis and have good prospects
in Chinese Medicine. These drugs are used for promoting
blood circulation for removing blood stasis (PBCRBS) and
are involved in the clinical treatment of cardiovascular-related
diseases, particularly as anti-thrombosis agents. Compared
to Western medicines, TCM herbs have advantages of
mild action, multiple pathways, multiple targets, and fewer
adverse reactions. According to the network pharmacology
analysis of PBCRBS herbs, the most frequently used TCMs
contain Danshen (Salvia miltiorrhiza Bge.), Chuanxiong
(Ligusticum chuanxiong hort), Honghua (Carthamus tinctorius
L.), Sanqi (Panax notoginseng Burk), and Danggui [Angelica
sinensis (Oliv.) Diels]. However, analyzing these herbs and
their compounds revealed that they mainly exerted anti-
thrombosis activity by affecting the nitric oxide synthase 2
(NOS2), prostaglandin-endoperoxide synthase 2 (PTGS2),
tumor necrosis factor (TNF), and interleukin 1 beta (IL-1β)
pathways. Currently, no research into the application of these
herbs/compounds to P2Y1 receptors is available. Because
the construction of MRS2500 and the combination model
between MRS2500 and P2Y1R has been established, numerous
TCMs can be utilized to treat thrombosis in a novel and
mild manner. A combination of antiplatelet dugs is more
efficient than a single drug at inhibiting the multiple pathways
of platelet activation. Furthermore, natural compounds
extracted from herbs have fewer side effects than synthetic
compounds. We investigated the herbs and their compounds
with anti-platelet aggregation activities similar to those of
MRS2500.
Overall, in this study, a total of 8987 compounds from TCMs
filtered by Lipinski’s rule of five were predicted have ideal oral-
intake properties. Among them, 1656 compounds distributed in
443 herbs were able to dock into the P2Y1R-MRS2500 structure
in 16,317 poses. A total of 38 compounds had a DockScore above
70.0 and may have significant potential for development into
anti-thrombosis drugs. We also investigated Cimicifuga foetida
L., Ganoderma lucidum Karst and Glycyrrhiza uralensis Fisch.
These herbs and their chemical constituents have not been widely
used in anti-thrombosis treatment andmay have potential as new
drugs for the inhibition of platelet aggregation.
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